Skip to content
Vivo logo
← All articles

Compounded Semaglutide Safety: What to Verify Before Use

Compounded Semaglutide Safety: What to Verify Before Use

Abstract geometric safety verification title card

Compounded semaglutide is not FDA-approved, and the FDA does not review it for safety, quality or effectiveness before it reaches a patient. Its safety therefore depends on who prescribes it, which pharmacy prepares it, what is in the vial and how the dose is measured. Each of those can be checked, and this article lists how.

Vivovivoclinic.orgKnow Who Prescribes and CompoundsVivo offers provider-supervised therapies prepared by licensed U.S. pharmacies, with personalized treatment selection and HIPAA-compliant data practices.Explore Vivo’s care

TL;DR

  • Compounded semaglutide has no FDA premarket review, so safety rests on the prescriber, a state-licensed pharmacy and clear dosing instructions.
  • The most common reported problems are dosing errors, gastrointestinal effects and, in some cases, products that differ from the approved active ingredient.
  • The FDA reported 990 adverse event reports for compounded semaglutide as of May 31, 2026, a figure that shows why monitoring matters.
  • Before starting, confirm a licensed prescriber, a licensed U.S. pharmacy, the exact ingredient on the label and a written dosing plan in milligrams and milliliters.
  • Whether compounded semaglutide remains available to a given patient is a regulatory question that has changed since 2025, so confirm it with a provider.

Table of Contents

Is compounded semaglutide safe?

The accurate answer is that it has not been proven safe in the way an approved drug has. The FDA states that compounded drugs do not undergo FDA premarket review for safety, quality or effectiveness, and that they should be used only when a patient’s needs cannot be met by an available FDA-approved drug.

That does not make every compounded preparation unsafe. Compounding is a legal, long-established practice in which a pharmacist prepares a medication for an individual patient on a prescription. Federal law addresses compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, by a physician, and in outsourcing facilities. The practical risk comes from variation: in ingredients, in sterility, in concentration and in the way instructions are written.

So the useful question is not whether compounded semaglutide is safe in general, but whether a specific product, from a specific pharmacy, prescribed by a specific licensed clinician, with specific instructions, meets the standards described below.

How compounded semaglutide differs from Ozempic and Wegovy

Ozempic and Wegovy are FDA-approved products with fixed formulations, standardized prefilled pens and labeling reviewed by the agency. Compounded semaglutide is prepared by a pharmacy for one patient, usually as a vial of liquid or a nasal or oral preparation, and it is not reviewed by the FDA as a finished product.

Factor FDA-approved semaglutide Compounded semaglutide
FDA premarket review Yes No
Typical container Prefilled pen with set dose markings Vial and syringe, or another pharmacy-defined format
Concentration Fixed by the manufacturer Set by the pharmacy, can differ between pharmacies
Dosing instructions Standardized in the label Written by the prescriber or pharmacy
Who is accountable Manufacturer under FDA oversight Prescriber and the licensed compounding pharmacy

The differences in container and concentration matter more than most patients expect. The FDA notes that dosing confusion may arise because compounded semaglutide can come in different containers and concentrations, and instructions may use units whose volume varies with concentration.

Is compounded semaglutide safer than Ozempic?

No evidence supports that. Approved products have been reviewed by the FDA for safety and manufacturing quality, and compounded products have not. Some patients are prescribed a compounded product because a provider judges a specific clinical need, such as an allergy to an ingredient in a commercial product, which the U.S. Pharmacopeia describes as one of the situations in which compounding meets a unique patient need. That is a clinical decision made by a prescriber, not a safety advantage.

What adverse events have been reported

The FDA has received reports of adverse events, including some requiring hospitalization, associated with compounded injectable semaglutide, often linked to dosing errors during self-administration or miscalculations by health care providers. Reported events include:

  • Nausea, vomiting and abdominal pain
  • Fainting, headache and migraine
  • Dehydration
  • Acute pancreatitis and gallstones

As of May 31, 2026, the FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 for compounded tirzepatide. These are voluntary reports, so they show that problems occur, not how often they occur.

An academic pharmacovigilance study of FDA adverse event data from 2018 to 2024 found higher reporting odds for abdominal pain, diarrhea, nausea, suicidality, cholecystitis and hospitalization with compounded GLP-1 receptor agonists than with non-compounded products. The authors note that this underscores the importance of rigorous quality standards and enhanced patient monitoring. Reporting databases have limits, which is a reason to treat the findings as a signal for careful oversight rather than a precise risk rate.

Gastrointestinal effects are also expected with semaglutide in general, including approved forms, and typically depend on dose and escalation speed. Our guide to semaglutide dose escalation explains why gradual titration under a prescriber’s direction matters.

Where the risks come from

Dosing errors

Dosing errors are the best-documented hazard. The FDA identifies causes including unfamiliarity with measuring medication from a vial, confusion between units, and health care providers miscalculating doses. An academic review of reports to poison centers found that vials lack the safety features of prefilled pens and allow large overdoses, and syringes with varying units can add to patient confusion.

Three causes of semaglutide dosing errors

A practical safeguard is to ask for the dose in two forms: milligrams of semaglutide and the exact volume in milliliters on the syringe. A prescription that gives only “units” or “clicks” without the concentration is incomplete. Needle and syringe selection also affects measuring accuracy, as covered in our peptide needle size and syringe guide, and our page on semaglutide injection sites describes rotation and technique.

Ingredient differences

Some compounded products use salt forms such as semaglutide sodium and semaglutide acetate. These differ from the active ingredient in approved drugs, and the FDA states it is not aware of a lawful basis for their use in compounding and lacks data on their properties. A patient should therefore read the label and ask the pharmacy to confirm which form of semaglutide is in the product.

Additives deserve the same attention. A 2025 academic search found that 48% of identified compounded semaglutide or tirzepatide products combined the drug with additives such as cyanocobalamin, glycine, niacinamide, docusate or ondansetron, and that evidence for subcutaneous ondansetron was lacking. A single-ingredient product is easier to evaluate than a blend.

Sterility, purity and potency

The U.S. Pharmacopeia states that compounded products may pose risks to sterility, purity and potency, which can lead to infections or ineffective treatment. Its chapters <795> (nonsterile) and <797> (sterile preparations) set the quality standards that responsible pharmacies follow. The adverse event analysis cited above also found significantly higher odds of documented preparation errors, prescribing errors, contamination and manufacturing issues in reports involving compounded GLP-1 products.

Counterfeit and illegally marketed products

The FDA has warned about fraudulent compounded semaglutide and tirzepatide marketed in the U.S. with false information on the label. Products sold as “research use only” or through sites with no prescriber are outside the licensed system entirely. A prescription requirement is the clearest line between a regulated pathway and an unregulated one.

Can you still get compounded semaglutide in the U.S.?

The regulatory position has tightened. The FDA determined, as of February 21, 2025, that the national shortage of semaglutide injection products is resolved. Under the agency’s published policy, 503A compounding must be for an individual patient based on a prescription and cannot regularly or in inordinate amounts make essentially copied drugs. Outsourcing facilities under section 503B cannot use bulk semaglutide, because it is not on the 503B bulks list or the shortage list.

On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list. The rules continue to develop, so the current status should be confirmed with the FDA pages above and with the prescribing provider. For clinicians, our note on 503A vs 503B shipments lists what to check when receiving product.

Safety checklist before starting

The FDA’s guidance for patients is to obtain a doctor’s prescription, fill it at a state-licensed pharmacy, ask the doctor or compounder about administration instructions or the label, and use the FDA’s BeSafeRx resources when buying medicine online. Translated into a working checklist:

  1. Prescriber. A licensed clinician reviews your medical history, current medications and goals before prescribing. Ask who the prescriber is and how to reach them.
  2. Pharmacy. The product is prepared by a state-licensed U.S. pharmacy. Ask for the pharmacy’s name and license state.
  3. Ingredient. The label names semaglutide base as the active ingredient, and any additives are disclosed.
  4. Dose. The written plan states milligrams, milliliters and the concentration, with a stepwise escalation schedule.
  5. Supplies and training. You receive sterile syringes and clear injection instructions, with a way to ask questions.
  6. Monitoring. There is a defined follow-up for side effects, and you know which symptoms need urgent care, such as severe or persistent abdominal pain, repeated vomiting or signs of dehydration.
  7. Privacy. The service handles health data under HIPAA.

People with a history of pancreatitis, gallbladder disease, a personal or family history of certain thyroid tumors, or who are pregnant or planning pregnancy should discuss semaglutide with a licensed clinician before any use. The prescriber, not an article, decides whether it is appropriate.

Our perspective

We view the safety question as a question of process. Compounded semaglutide is a prescription therapy, and its risks are best managed by the same things that manage any prescription: a licensed provider who reviews the patient, a licensed U.S. pharmacy that prepares the product, and written instructions that leave no room to guess the dose.

Our telehealth model is built around that sequence. Patients complete a HIPAA-compliant intake, a provider reviews the information and decides whether a plan is appropriate, and approved therapies are prepared by licensed U.S. pharmacies and shipped to the patient’s home with ongoing provider oversight. We hold that this structure, with personalized treatment selection and supervision, is what a patient should expect from any service offering compounded GLP-1 therapy.

We also think patients are right to ask direct questions about the pharmacy, the ingredient and the dose before starting. A provider that welcomes those questions is easier to trust than one that avoids them.

Jack

How Vivo approaches compounded semaglutide

Our compounded semaglutide and compounded tirzepatide pages describe the process, from intake to provider review to shipment from a licensed U.S. pharmacy. The combined Tirzepatide & Semaglutide plan is listed at $199 per month, with provider supervision included. Treatment is prescribed only after a provider reviews eligibility, and not every applicant is approved. For a clinical comparison of the two medications, see our tirzepatide vs semaglutide review.

Questions to ask any provider

  • Who is the prescribing clinician, and what is their license state?
  • Which pharmacy prepares the medication, and is it a 503A pharmacy licensed in my state?
  • Does the label list semaglutide base, and are there any additives?
  • What is the concentration, and how many milliliters equal each dose?
  • What is the escalation schedule, and what should I do if I miss a dose?
  • How do I report a side effect, and who responds?
  • If compounded semaglutide becomes unavailable to me, what is the plan for continuing care?

FAQ

Is compounded semaglutide safe?

It has not been proven safe the way an FDA-approved drug has, because the FDA does not review compounded drugs before they are marketed. Risk is reduced by using a licensed prescriber, a state-licensed pharmacy, a clearly labeled product and a written dose in milligrams and milliliters. Discuss your medical history with a licensed clinician before starting.

Is the FDA going to stop compounded semaglutide?

The FDA has stated that the semaglutide shortage is resolved and that its enforcement flexibility for essentially copied products has ended, and it proposed on April 30, 2026 to exclude semaglutide from the 503B bulk drug substances list. Compounding for an individual patient under section 503A remains subject to the conditions the agency has published. Check the FDA’s compounding pages and your provider for current status.

What are the most common compounded semaglutide side effects?

Reported events include nausea, vomiting, abdominal pain, headache, dehydration, pancreatitis and gallstones. Many of the serious reports involved dosing errors. Contact a clinician promptly for severe or persistent abdominal pain or repeated vomiting.

How can I avoid dosing mistakes with a vial?

Ask for the dose in both milligrams and milliliters, confirm the concentration on the label, and use the syringe the pharmacy provides. Have the prescriber or pharmacist show you the first measurement if you have not used a vial before. Never combine instructions from different products.

Is compounded semaglutide the same as Ozempic?

No. Ozempic is an FDA-approved product with a fixed formulation and a prefilled pen. Compounded semaglutide is prepared by a pharmacy for an individual patient and is not FDA-approved.

Sources